Injectafer Lawsuit Updates

Severe and prolonged low blood phosphorous levels could result in heart problems and death. Learn more about the latest Injectafer lawsuit update and Injectafer settlement informtion

Side effects of the iron deficiency drug Injectafer may result in severely low phosphorous levels, which could result in serious and potentially life-threatening injuries. Injectafer lawsuits are being pursued against the drug makers, for failing to adequately warn users and the medical community.

INJECTAFER LAWSUIT CRITERIA: Free consultations and case evaluations are being provided by Injectafer lawyers to determine whether financial compensation or settlements may be available for individuals who have developed a condition known as severe hypophosphatemia (HPP).

This Injectafer side effect may result in:

  • Cardiac arrest
  • Respiratory failure
  • Seizures
  • Muscle weakness
  • Coma
  • Death

CONTACT AN INJECTAFER LAWYER

Find out if you or a loved one may be eligible for an Injectafer settlement. Lawyers review cases on a contingency fee basis, which means there are no fees or expenses unless you win.

CONTACT A LAWYER

Latest Injectafer Lawsuit Updates 2022

September 2022 Update: U.S. District Judge Wendy Beetlestone has scheduled the first Injectafer trial to begin on June 5, 2023. While the outcome will not be binding on other lawsuits, it may have a big impact on any Injectafer settlement negotiations to avoid the need for each case to go to trial.

August 2021 Update: With dozens of Injectafer lawsuits moving forward in the Eastern District of Pennsylvania, each involving similar allegations that the drug maker failed to warn about side effects of the iron infusion, a motion was filed to consolidate two cases for trial to conserve judicial resources and better gauge how juries will respond to certain evidence and testimony that will be repeated throughout the litigation. However, the Court has determined that the first two Injectafer bellwether cases will go to trial separately.

August 2019 Update: In a study published this month supported the allegations raised in a growing number of lawsuits, indicating that Injectafer side effects can cause hypophosphatemia (HPP), involving dangerously low phosphorus levels.


Injectafer Litigation Overview

MANUFACTURER: American Regent, a subsidiary of Daiichi Sankyo.

OVERVIEW: Injectafer (ferric carboxymaltose) is an iron infusion delivered through an intravenous injection for adults with anemia, for whom oral iron supplements can not be used and who have non-dialysis dependent chronic kidney disease.

Originally created by Vifor Pharmaceuticals, the Injectafer injection was approved for use in the United States in 2013 and marketed by Luitpold Pharmaceuticals, which then merged with Daiichi Sankyo subsidiary, American Regent.

While the medication was sold as a safe and effective treatment, increasing evidence suggests that the drug makers knew about serious Injectafer side effects and withheld information from users, doctors and regulators as part of a scheme to place profits before patient safety.

INJECTAFER SEVERE HPP RISKS: Studies dating back years have suggested potential Injectafer problems may include the potential to dangerously lower blood phosphorous levels. In fact, the original new drug application for Injectafer was rejected by the FDA in 2006, indicating that “clinically important hypophosphatemia” was one of the safety concerns by FDA reviewers.

In 2015, a study published in the International Journal of Rheumatology warned that 13% of patients receiving Injectafer developed severe and prolonged hypophosphatemia.

According to another study published in PLoS One in December 2016, a “high risk” of developing severe and prolonged HPP was linked to use of Ferinject, which is a brand name for the drug sold outside the U.S., containing the same active ingredient as Injectafer.

More recently, a July 2019 study in Alimentary Pharmacology and Therapeutics found high rates of severe and persistent HPP in patients with inflammatory bowel disease given Injectafer.

HPP is a disturbance of the body’s electrolytes caused by low levels of phosphate in the blood. Some research has suggested that FCM increases the production of fibroblast growth factor 23 hormones in the body. Increases of this hormone are known to cause HPP.

In February 2020, an update was made to the Injectafer FDA label about the hypophosphatemia risk. However, this information remains inadequate and fails to properly disclose the serious risks that users may face, and the importance of monitoring blood phosphate levels after the iron injection.

Find Out If You Qualify for an Injectafer Settlement

As a result of the drug makers’ failure to adequately warn about the risks associated with their medication, Injectafer lawyers are evaluating whether users may be entitled to compensation through a product liability lawsuit or class action lawsuit.

According to allegations presented in the claims, Daiichi Sankyo and it’s American Regent ahd Luitpold Pharmaceuticals subsidiaries withheld important safety information about the HPP risks from Injectafer, and provided false and misleading label warnings and information about Injectafer’s safety for years.

To request a free consultation and claim evaluation to determine whether you, a friend or family member may be entitled to financial compensation through a lawsuit, submit information for review to an Injectafer injury lawyer.

2 Comments

  • PatriciaAugust 21, 2022 at 12:26 pm

    my heart has been affected after taking this medication but was not warn of side effect, after i look up he medication , then i knew i was affected, please help

  • MichelleNovember 17, 2020 at 5:02 am

    I have been severely ill following my iron infusions

"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories